-
Je něco špatně v tomto záznamu ?
Semaglutide and NT-proBNP in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program
MC. Petrie, BA. Borlaug, J. Butler, MJ. Davies, DW. Kitzman, SJ. Shah, S. Verma, TJ. Jensen, MN. Einfeldt, K. Liisberg, E. Perna, K. Sharma, JA. Ezekowitz, M. Fu, V. Melenovský, H. Ito, M. Lelonek, MN. Kosiborod, STEP-HFpEF Trial Committees and...
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, randomizované kontrolované studie, multicentrická studie
NLK
Free Medical Journals
od 1983 do Před 1 rokem
Open Access Digital Library
od 1998-01-01
- MeSH
- dvojitá slepá metoda MeSH
- glukagonu podobné peptidy * terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- natriuretický peptid typu B * krev MeSH
- obezita * krev komplikace farmakoterapie MeSH
- peptidové fragmenty * krev MeSH
- senioři MeSH
- srdeční selhání * farmakoterapie krev patofyziologie MeSH
- tepový objem * účinky léků fyziologie MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- randomizované kontrolované studie MeSH
BACKGROUND: The glucagon-like peptide-1 receptor agonist, semaglutide, improved health status and reduced body weight in patients with obesity-related heart failure (HF) with preserved ejection fraction (HFpEF) in the STEP-HFpEF (Semaglutide Treatment Effect in People with Obesity and HFpEF) program. Whether benefits were due to mechanical unloading or effects on HF pathobiology is uncertain. OBJECTIVES: This study sought to determine if semaglutide 2.4 mg reduced N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with obesity-related HFpEF and compare treatment responses by baseline NT-proBNP. METHODS: This was a prespecified secondary analysis of pooled data from 2 double-blind, placebo-controlled, randomized trials (STEP-HFpEF [Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity] and STEP-HFpEF DM [Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes]) testing effects of semaglutide in patients with obesity-related HFpEF. The main outcomes were change in NT-proBNP at 52 weeks and change in the dual primary endpoints of Kansas City Cardiomyopathy Questionnaire Clinical Summary Score and body weight by baseline NT-proBNP. RESULTS: In total, 1,145 patients were randomized. Semaglutide compared with placebo reduced NT-proBNP at 52 weeks (estimated treatment ratio: 0.82; 95% CI: 0.74-0.91; P = 0.0002). Improvements in health status were more pronounced in those with higher vs lower baseline NT-proBNP (estimated difference: tertile 1: 4.5 points, 95% CI: 0.8-8.2; tertile 2: 6.2 points, 95% CI: 2.4-10.0; tertile 3: 11.9 points, 95% CI: 8.1-15.7; P interaction = 0.02; baseline NT-proBNP as a continuous variable: P interaction = 0.004). Reductions in body weight were consistent across baseline NT-proBNP levels (P interaction = 0.21). CONCLUSIONS: In patients with obesity-related HFpEF, semaglutide reduced NT-proBNP. Participants with higher baseline NT-proBNP had a similar degree of weight loss but experienced larger reductions in HF-related symptoms and physical limitations with semaglutide than those with lower NT-proBNP.
Baylor Scott and White Research Institute Dallas Texas USA
Department of Cardiovascular Medicine Mayo Clinic Rochester Minnesota USA
Department of General Internal Medicine 3 Kawasaki Medical School Okayama Japan
Department of Medicine University of Mississippi Jackson Mississippi USA
Department of Noninvasive Cardiology Medical University of Lodz Lodz Poland
Diabetes Research Centre University of Leicester Leicester United Kingdom
Division of Cardiology The Johns Hopkins University School of Medicine Baltimore Maryland USA
Institute for Clinical and Experimental Medicine Prague Czech Republic
Instituto de Cardiología de Corrientes J F Cabral Corrientes Argentina
NIHR Leicester Biomedical Research Centre Leicester United Kingdom
Novo Nordisk A S Søborg Denmark
School of Cardiovascular and Metabolic Health University of Glasgow Glasgow United Kingdom
Section of Cardiology Department of Medicine Sahlgrenska University Hospital Ostra Gothenburg Sweden
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24013334
- 003
- CZ-PrNML
- 005
- 20240905133503.0
- 007
- ta
- 008
- 240725s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jacc.2024.04.022 $2 doi
- 035 __
- $a (PubMed)38819334
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Petrie, Mark C $u School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom
- 245 10
- $a Semaglutide and NT-proBNP in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program / $c MC. Petrie, BA. Borlaug, J. Butler, MJ. Davies, DW. Kitzman, SJ. Shah, S. Verma, TJ. Jensen, MN. Einfeldt, K. Liisberg, E. Perna, K. Sharma, JA. Ezekowitz, M. Fu, V. Melenovský, H. Ito, M. Lelonek, MN. Kosiborod, STEP-HFpEF Trial Committees and Investigators
- 520 9_
- $a BACKGROUND: The glucagon-like peptide-1 receptor agonist, semaglutide, improved health status and reduced body weight in patients with obesity-related heart failure (HF) with preserved ejection fraction (HFpEF) in the STEP-HFpEF (Semaglutide Treatment Effect in People with Obesity and HFpEF) program. Whether benefits were due to mechanical unloading or effects on HF pathobiology is uncertain. OBJECTIVES: This study sought to determine if semaglutide 2.4 mg reduced N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with obesity-related HFpEF and compare treatment responses by baseline NT-proBNP. METHODS: This was a prespecified secondary analysis of pooled data from 2 double-blind, placebo-controlled, randomized trials (STEP-HFpEF [Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity] and STEP-HFpEF DM [Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes]) testing effects of semaglutide in patients with obesity-related HFpEF. The main outcomes were change in NT-proBNP at 52 weeks and change in the dual primary endpoints of Kansas City Cardiomyopathy Questionnaire Clinical Summary Score and body weight by baseline NT-proBNP. RESULTS: In total, 1,145 patients were randomized. Semaglutide compared with placebo reduced NT-proBNP at 52 weeks (estimated treatment ratio: 0.82; 95% CI: 0.74-0.91; P = 0.0002). Improvements in health status were more pronounced in those with higher vs lower baseline NT-proBNP (estimated difference: tertile 1: 4.5 points, 95% CI: 0.8-8.2; tertile 2: 6.2 points, 95% CI: 2.4-10.0; tertile 3: 11.9 points, 95% CI: 8.1-15.7; P interaction = 0.02; baseline NT-proBNP as a continuous variable: P interaction = 0.004). Reductions in body weight were consistent across baseline NT-proBNP levels (P interaction = 0.21). CONCLUSIONS: In patients with obesity-related HFpEF, semaglutide reduced NT-proBNP. Participants with higher baseline NT-proBNP had a similar degree of weight loss but experienced larger reductions in HF-related symptoms and physical limitations with semaglutide than those with lower NT-proBNP.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a natriuretický peptid typu B $x krev $7 D020097
- 650 12
- $a srdeční selhání $x farmakoterapie $x krev $x patofyziologie $7 D006333
- 650 12
- $a peptidové fragmenty $x krev $7 D010446
- 650 12
- $a glukagonu podobné peptidy $x terapeutické užití $7 D004763
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a obezita $x krev $x komplikace $x farmakoterapie $7 D009765
- 650 12
- $a tepový objem $x účinky léků $x fyziologie $7 D013318
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Borlaug, Barry A $u Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA
- 700 1_
- $a Butler, Javed $u Baylor Scott and White Research Institute, Dallas, Texas, USA; Department of Medicine, University of Mississippi, Jackson, Mississippi, USA
- 700 1_
- $a Davies, Melanie J $u Diabetes Research Centre, University of Leicester, Leicester, United Kingdom; NIHR Leicester Biomedical Research Centre, Leicester, United Kingdom
- 700 1_
- $a Kitzman, Dalane W $u Department of Cardiovascular Medicine and Section on Geriatrics and Gerontology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
- 700 1_
- $a Shah, Sanjiv J $u Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
- 700 1_
- $a Verma, Subodh $u Division of Cardiac Surgery, Li Ka Shing Knowledge Institute of St Michael's Hospital, Unity Health Toronto, University of Toronto, Toronto, Ontario, Canada
- 700 1_
- $a Jensen, Thomas Jon $u Novo Nordisk A/S, Søborg, Denmark
- 700 1_
- $a Einfeldt, Mette Nygaard $u Novo Nordisk A/S, Søborg, Denmark
- 700 1_
- $a Liisberg, Karoline $u Novo Nordisk A/S, Søborg, Denmark
- 700 1_
- $a Perna, Eduardo $u Instituto de Cardiología de Corrientes J. F. Cabral, Corrientes, Argentina
- 700 1_
- $a Sharma, Kavita $u Division of Cardiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
- 700 1_
- $a Ezekowitz, Justin A $u University of Alberta, Edmonton, Alberta, Canada
- 700 1_
- $a Fu, Michael $u Section of Cardiology, Department of Medicine, Sahlgrenska University Hospital-Ostra, Gothenburg, Sweden
- 700 1_
- $a Melenovský, Vojtěch $u Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Ito, Hiroshi $u Department of General Internal Medicine 3, Kawasaki Medical School, Okayama, Japan
- 700 1_
- $a Lelonek, Małgorzata $u Department of Noninvasive Cardiology, Medical University of Lodz, Lodz, Poland
- 700 1_
- $a Kosiborod, Mikhail N $u Department of Cardiovascular Disease, Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA. Electronic address: mkosiborod@saint-lukes.org
- 710 2_
- $a STEP-HFpEF Trial Committees and Investigators
- 773 0_
- $w MED00002964 $t Journal of the American College of Cardiology $x 1558-3597 $g Roč. 84, č. 1 (2024), s. 27-40
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38819334 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905133457 $b ABA008
- 999 __
- $a ok $b bmc $g 2143256 $s 1225200
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 84 $c 1 $d 27-40 $e 20240513 $i 1558-3597 $m Journal of the American College of Cardiology $n J Am Coll Cardiol $x MED00002964
- LZP __
- $a Pubmed-20240725
